Tower Bridge Advisors Sells 1,987 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Tower Bridge Advisors trimmed its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 2.7% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 72,068 shares of the medical research company's stock after selling 1,987 shares during the quarter. IQVIA makes up 1.4% of Tower Bridge Advisors' portfolio, making the stock its 18th biggest holding. Tower Bridge Advisors' holdings in IQVIA were worth $12,706,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently added to or reduced their stakes in the company. American National Bank & Trust acquired a new position in IQVIA in the first quarter valued at $26,000. Golden State Wealth Management LLC increased its stake in IQVIA by 295.5% in the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company's stock valued at $31,000 after purchasing an additional 130 shares during the last quarter. AllSquare Wealth Management LLC acquired a new position in IQVIA in the first quarter valued at $33,000. ST Germain D J Co. Inc. increased its stake in IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company's stock valued at $34,000 after purchasing an additional 76 shares during the last quarter. Finally, GKV Capital Management Co. Inc. acquired a new position in IQVIA in the fourth quarter valued at $39,000. 89.62% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

IQV has been the subject of several research analyst reports. William Blair restated an "outperform" rating on shares of IQVIA in a research note on Wednesday, July 23rd. Citigroup restated a "neutral" rating on shares of IQVIA in a research note on Thursday, May 22nd. JPMorgan Chase & Co. decreased their target price on IQVIA from $232.00 to $177.00 and set an "overweight" rating for the company in a research report on Monday, May 19th. Redburn Partners set a $188.00 target price on IQVIA in a research report on Friday, May 23rd. Finally, Cowen reaffirmed a "buy" rating on shares of IQVIA in a research report on Wednesday, July 23rd. Seven research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat, IQVIA currently has a consensus rating of "Moderate Buy" and a consensus price target of $228.62.

IQVIA Price Performance

Shares of IQV traded down $3.42 during trading hours on Friday, hitting $182.44. 1,644,130 shares of the company were exchanged, compared to its average volume of 2,034,876. The company has a market capitalization of $31.01 billion, a PE ratio of 26.40, a PEG ratio of 2.10 and a beta of 1.30. The company has a debt-to-equity ratio of 2.45, a current ratio of 0.84 and a quick ratio of 0.84. The firm has a fifty day simple moving average of $161.20 and a 200-day simple moving average of $170.18. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $252.88.

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping the consensus estimate of $2.77 by $0.04. The business had revenue of $4.02 billion during the quarter, compared to analysts' expectations of $3.96 billion. IQVIA had a return on equity of 30.05% and a net margin of 7.88%. IQVIA's revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the firm posted $2.64 earnings per share. As a group, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Insider Transactions at IQVIA

In related news, insider Eric Sherbet sold 5,800 shares of the business's stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the completion of the transaction, the insider owned 27,178 shares in the company, valued at $5,165,178.90. The trade was a 17.59% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Keriann Cherofsky sold 549 shares of the business's stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares of the company's stock, valued at $557,352.30. This trade represents a 15.87% decrease in their position. The disclosure for this sale can be found here. Insiders own 1.60% of the company's stock.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.